NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biotech’

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

15 April 2014

Column Group nears $200m mark for second fund

biotech_lrg Biotech-focused investment firm The Column Group has passed the halfway mark for its $250m-targeting second venture capital fund, according to documents filed with US securities regulators.

8 April 2014

Deerfield secures $1.6bn for third fund

Healthcare-focused investment firm Deerfield Management Company has secured $1.6bn for its third fund.

8 April 2014

Lightstone Ventures secures more than $150m for debut fundp

life science test tube_sq Life sciences-focused venture capital firm Lightstone Ventures has passed the halfway mark for its debut fund, AltAssets has learned.

3 April 2014

Intarcia Therapeutics scores $200m round

biotech_lrg Venture capital firm RA Capital has led a massive $200m round for biotech startup Intarcia Therapeutics.

24 March 2014

Venture capital-backed Versartis soars after IPO

graph_positive_170sq Venture capital-backed Versartis soars after IPO

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

11 March 2014

Lumena Pharmaceuticals raises $45m in NEA-led Series B

biotech_lrg New Enterprise Associates led a $45m Series B round for biopharmaceutical company Lumena Pharmaceuticals, which is focused on developing products for rare cholestatic liver diseases and serious metabolic disorders.

4 March 2014

Foresite Capital nears $300m target for second healthcare fundp

biotech_lrg Healthcare-focused growth capital firm Foresite Capital is nearing a final close for its second fund, AltAssets can reveal.

17 February 2014

Mega buyout boosts biotech private equity activityp

The value of private equity, venture capital and development capital investment targeting biotechnology companies started 2014 on an impressive note, leaping to its highest point in the last 12 months.

Page 1 of 812345...Last »

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014